Biopharmaceutical company Hybrigenics, based in Paris, has signed a contract as part of the European Union research project Masterswitch. The company will receive more than €400,000 over the first two years of the five-year agreement, which will enable it to develop a high-throughput assay and attempt to identify small-molecule inhibitors of a protein reaction found in chronic inflammatory diseases.